Matthias Kalder1, Konstantinos Pantazis, Konstantinos Dinas, Ute-Susann Albert, Christina Heilmaier, Karel Kostev. 1. Department of Obstetrics and Gynecology, Philipps University of Marburg, Marburg, FOM University of Applied Sciences, Essen, and IMS Health, Frankfurt, Germany; and the 1st Department of Obstetrics and Gynecology and the 2nd Department of Obstetrics and Gynecology, Medical School, Aristotle University, Thessaloniki, Greece.
Abstract
OBJECTIVE: To evaluate the discontinuation rates of anticholinergics prescribed in patients with urinary incontinence (UI). METHODS: Data from a Disease Analyzer database including 988 general, 95 urologist, and 203 gynecologic practices were examined. Twenty six thousand eight hundred thirty-four patients were identified as having received a first-time anticholinergic prescription for UI, namely darifenacin, fesoterodine, oxybutynin, propiverine, solifenacin, tolterodine, or trospium, between 2005 and 2012. Covariates studied included demographic data, concomitant diagnoses, and potential drug-induced side effects. The cumulative discontinuation rate of initial treatment was estimated using a Kaplan-Meier analysis. A Cox proportional hazard regression model was used to estimate the relationship between discontinuation and the demographic and clinical variables for up to 36 months. RESULTS: An increasing discontinuation rate was observed in years 1, 2, and 3 (74.8%, 77.6%, 87%). Within 3 years, discontinuation rates were higher for men than for women (87.9%, 86.5%; P=.056; hazard ratio [HR] 1.14, 95% confidence interval [CI] 1.11-1.18; P<.001), for patients treated in gynecologic practices and general practices than those treated in urologist practices (HR 1.60; 95% CI 1.52-1.67, P<.001 and HR 1.24, 95% CI 1.20-1.29, P<.001, respectively) and for younger patients than those older than 80 year old (60 years or younger, HR 1.27, 95% CI 1.22-1.33; 61-70 years, HR 1.16, 95% CI 1.11-1.21; 71-80 years, HR 1.14, 95% CI 1.09-1.18, P<.001). Those using propiverine or solifenacin were less likely to discontinue treatment than those using oxybutynin (HR 0.94, 95% CI 0.88-0.99, P=.024 and HR 0.93, 95% CI 0.87-0.98, P=.004, respectively). CONCLUSION: Patients with UI demonstrate high discontinuation rates for anticholinergics with only slight variations between the various drugs in this category. LEVEL OF EVIDENCE: : III.
OBJECTIVE: To evaluate the discontinuation rates of anticholinergics prescribed in patients with urinary incontinence (UI). METHODS: Data from a Disease Analyzer database including 988 general, 95 urologist, and 203 gynecologic practices were examined. Twenty six thousand eight hundred thirty-four patients were identified as having received a first-time anticholinergic prescription for UI, namely darifenacin, fesoterodine, oxybutynin, propiverine, solifenacin, tolterodine, or trospium, between 2005 and 2012. Covariates studied included demographic data, concomitant diagnoses, and potential drug-induced side effects. The cumulative discontinuation rate of initial treatment was estimated using a Kaplan-Meier analysis. A Cox proportional hazard regression model was used to estimate the relationship between discontinuation and the demographic and clinical variables for up to 36 months. RESULTS: An increasing discontinuation rate was observed in years 1, 2, and 3 (74.8%, 77.6%, 87%). Within 3 years, discontinuation rates were higher for men than for women (87.9%, 86.5%; P=.056; hazard ratio [HR] 1.14, 95% confidence interval [CI] 1.11-1.18; P<.001), for patients treated in gynecologic practices and general practices than those treated in urologist practices (HR 1.60; 95% CI 1.52-1.67, P<.001 and HR 1.24, 95% CI 1.20-1.29, P<.001, respectively) and for younger patients than those older than 80 year old (60 years or younger, HR 1.27, 95% CI 1.22-1.33; 61-70 years, HR 1.16, 95% CI 1.11-1.21; 71-80 years, HR 1.14, 95% CI 1.09-1.18, P<.001). Those using propiverine or solifenacin were less likely to discontinue treatment than those using oxybutynin (HR 0.94, 95% CI 0.88-0.99, P=.024 and HR 0.93, 95% CI 0.87-0.98, P=.004, respectively). CONCLUSION:Patients with UI demonstrate high discontinuation rates for anticholinergics with only slight variations between the various drugs in this category. LEVEL OF EVIDENCE: : III.
Authors: Christopher J D Wallis; Colin Lundeen; Nicole Golda; Hilary Brotherhood; Peter Pommerville; Lesley Carr Journal: Can Urol Assoc J Date: 2016-08 Impact factor: 1.862
Authors: Alexis M Tran; Peter K Sand; Miriam J Seitz; Adam Gafni-Kane; Ying Zhou; Sylvia M Botros Journal: Int Urogynecol J Date: 2016-08-18 Impact factor: 2.894
Authors: Stefanie N Foster; Theresa M Spitznagle; Lori J Tuttle; Siobhan Sutcliffe; Karen Steger-May; Jerry L Lowder; Melanie R Meister; Chiara Ghetti; Jinli Wang; Michael J Mueller; Marcie Harris-Hayes Journal: J Womens Health Phys Therap Date: 2021 Jul-Sep
Authors: Önder Ercan; Bülent Köstü; Murat Bakacak; Yusuf Aytaç-Tohma; Bora Çoşkun; Fazıl Avcı; Erkan Efe Journal: Saudi Med J Date: 2015-10 Impact factor: 1.484